VKORC1 and CYP2C9 genotypes are predictors of warfarin‐related outcomes in children
Pediatric Blood & Cancer2014Vol. 61(6), pp. 1055–1062
Citations Over TimeTop 10% of 2014 papers
Kaitlyn Shaw, Ursula Amstutz, Claudette Hildebrand, Shahrad R. Rassekh, Martin Hosking, Kathleen Neville, J. Steven Leeder, Michael R. Hayden, Colin J.D. Ross, Bruce Carleton
Abstract
This study confirms the importance of VKORC1/CYP2C9 genotypes for warfarin dosing in a young pediatric cohort and demonstrates an impact of genetic factors on clinical outcomes in children. Furthermore, we identified an additional variant in CYP2C9 of potential relevance for warfarin dosing in children.
Related Papers
- → Role of Warfarin Pharmacogenetic Testing in Clinical Practice(2010)60 cited
- Warfarin Therapy and VKORC1 and CYP Genotype(2018)
- → Enzyme polymorphism in warfarin dose management after pediatric cardiac surgery(2015)8 cited
- → Clinical Effect of CYP2C9*5/*6 Genotype on a Patient’s Warfarin Dose Requirement(2017)7 cited
- → CYP2C9 Mutation Affecting the Individual Variability of Warfarin Dose Requirement(2012)4 cited